永泰生物-B(06978.HK)擬在北京興建新生物藥物研發及產業化基地
格隆匯 3 月 29日丨永泰生物-B(06978.HK)發佈公吿,2021年3月26日,公司透過其間接全資附屬公司北京永泰與中建三局訂立建造協議,內容有關在北京興建研發及產業化基地,合約金額為人民幣6.65億元。
公吿表示,2020年,集團成功投得一幅位於北京市北京經濟技術開發區路南區的地塊,用作建造一個具規模的生產中心,作為集團增長計劃的一部分。此外,由於集團核心在研產品EAL®是基於活體細胞生產,而活體細胞需要在有限時間內送達,集團長久以來的計劃為在中國主要城市(包括北京)距離中國人口稠密的地區不遠的地方建立生產中心。
為配合及籌備集團核心在研產品及其他在研產品的商業化,集團有意在位於北京的該土地上興建研發及產業化基地。尤其是,建造工程包括多幢用作細胞療法及其他生產車間及質檢的建築物,可讓集團因應集團核心在研產品及其他在研產品的商業化進行必要的研發工作、測試及質量保證程序。
因此,北京永泰訂立建造協議與上述意向及集團的業務策略一致,故此,董事會認為建造協議乃北京永泰與中建三局經公平磋商後,按一般商業條款訂立,而建造工程屬公平及合理,並符合公司及股東整體的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.